WO2006054304A3 - Use of lipid conjugates in the treatment of disease - Google Patents

Use of lipid conjugates in the treatment of disease Download PDF

Info

Publication number
WO2006054304A3
WO2006054304A3 PCT/IL2005/001225 IL2005001225W WO2006054304A3 WO 2006054304 A3 WO2006054304 A3 WO 2006054304A3 IL 2005001225 W IL2005001225 W IL 2005001225W WO 2006054304 A3 WO2006054304 A3 WO 2006054304A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
lipid
treatment
dimer
oligomer
Prior art date
Application number
PCT/IL2005/001225
Other languages
French (fr)
Other versions
WO2006054304A2 (en
Inventor
Saul Yedgar
Original Assignee
Yissum Res Dev Co
Saul Yedgar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/989,606 external-priority patent/US7811999B2/en
Priority claimed from US10/989,607 external-priority patent/US7772196B2/en
Priority claimed from PCT/US2005/006591 external-priority patent/WO2005084307A2/en
Priority to JP2007542507A priority Critical patent/JP2008520650A/en
Priority to CN2005800467713A priority patent/CN101175499B/en
Priority to BRPI0516810-4A priority patent/BRPI0516810A/en
Priority to CA002587883A priority patent/CA2587883A1/en
Priority to EA200701077A priority patent/EA012138B1/en
Priority to EP05808267A priority patent/EP1819345A4/en
Application filed by Yissum Res Dev Co, Saul Yedgar filed Critical Yissum Res Dev Co
Priority to AU2005305456A priority patent/AU2005305456B2/en
Priority to MX2007005975A priority patent/MX2007005975A/en
Priority to US11/285,375 priority patent/US8076312B2/en
Publication of WO2006054304A2 publication Critical patent/WO2006054304A2/en
Publication of WO2006054304A3 publication Critical patent/WO2006054304A3/en
Priority to IL183227A priority patent/IL183227A0/en
Priority to IL212214A priority patent/IL212214A0/en
Priority to IL212215A priority patent/IL212215A0/en
Priority to US13/283,020 priority patent/US8859524B2/en
Priority to US13/316,592 priority patent/US8906882B2/en
Priority to US13/788,325 priority patent/US20140005115A1/en
Priority to IL229980A priority patent/IL229980A0/en
Priority to IL229982A priority patent/IL229982A0/en
Priority to IL229981A priority patent/IL229981A0/en
Priority to US14/329,191 priority patent/US20140323434A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

This invention provides for the use of a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, for the preparation of a composition for treating a subject suffering from asthma, allergic rhinitis, or chronic obstructive pulmonary disease. This invention also provides for the use of a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, for the preparation of a composition for preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject.
PCT/IL2005/001225 2000-01-10 2005-11-17 Use of lipid conjugates in the treatment of disease WO2006054304A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MX2007005975A MX2007005975A (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease.
AU2005305456A AU2005305456B2 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease
EP05808267A EP1819345A4 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease
CN2005800467713A CN101175499B (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease
BRPI0516810-4A BRPI0516810A (en) 2004-11-17 2005-11-17 use of lipid conjugates in the treatment of diseases
CA002587883A CA2587883A1 (en) 2004-11-17 2005-11-17 Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
EA200701077A EA012138B1 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of diseases
JP2007542507A JP2008520650A (en) 2004-11-17 2005-11-17 Use of lipid complexes in disease treatment
US11/285,375 US8076312B2 (en) 2000-01-10 2005-11-23 Use of lipid conjugates in the treatment of disease
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease
IL212215A IL212215A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease
US13/283,020 US8859524B2 (en) 2005-11-17 2011-10-27 Lipid conjugates in the treatment of chronic rhinosinusitis
US13/316,592 US8906882B2 (en) 2005-11-17 2011-12-12 Lipid conjugates in the treatment of allergic rhinitis
US13/788,325 US20140005115A1 (en) 2005-11-17 2013-03-07 Lipid conjugates in the treatment of bronchitis
IL229981A IL229981A0 (en) 2004-11-17 2013-12-17 Use of lipid conjugates in the treatment of disease
IL229980A IL229980A0 (en) 2004-11-17 2013-12-17 Use of lipid conjugates in the treatment of disease
IL229982A IL229982A0 (en) 2004-11-17 2013-12-17 Use of lipid conjugates in the treatment of disease
US14/329,191 US20140323434A1 (en) 2005-11-17 2014-07-11 Lipid conjugates in the treatment of chronic rfhinosinusitis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/989,607 2004-11-17
US10/989,606 2004-11-17
US10/989,606 US7811999B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
US10/989,607 US7772196B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
PCT/US2005/006591 WO2005084307A2 (en) 2004-03-02 2005-03-02 Use of lipid conjugates in the treatment of disease
USPCT/US2005/006591 2005-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/463,792 Continuation-In-Part US20090325876A1 (en) 2000-01-10 2009-05-11 Use of lipid conjugates in the treatment of diseases associated with vasculature

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/756,765 Continuation-In-Part US7034006B2 (en) 2000-01-10 2001-01-10 Use of lipid conjugates in the treatment of disease
US11/285,375 Continuation-In-Part US8076312B2 (en) 2000-01-10 2005-11-23 Use of lipid conjugates in the treatment of disease

Publications (2)

Publication Number Publication Date
WO2006054304A2 WO2006054304A2 (en) 2006-05-26
WO2006054304A3 true WO2006054304A3 (en) 2007-01-25

Family

ID=39619055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/001225 WO2006054304A2 (en) 2000-01-10 2005-11-17 Use of lipid conjugates in the treatment of disease

Country Status (10)

Country Link
EP (1) EP1819345A4 (en)
JP (2) JP2008520650A (en)
CN (1) CN101175499B (en)
AU (1) AU2005305456B2 (en)
BR (1) BRPI0516810A (en)
CA (1) CA2587883A1 (en)
EA (1) EA012138B1 (en)
IL (3) IL183227A0 (en)
MX (1) MX2007005975A (en)
WO (1) WO2006054304A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US20100035843A1 (en) * 2007-02-12 2010-02-11 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
EP2429532A4 (en) * 2009-05-11 2015-05-27 Yissum Res Dev Co Lipid-polymer conjugates, their preparation and uses thereof
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2015005459A1 (en) * 2013-07-10 2015-01-15 生化学工業株式会社 Pharmaceutical composition for respiratory administration
KR20190097022A (en) 2016-11-17 2019-08-20 레노비온, 아이엔씨. Treatment of Respiratory Diseases and Infections with Glutathione Compositions
CA3082900A1 (en) 2017-11-17 2019-05-23 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064817A (en) * 1987-10-23 1991-11-12 Yissum Research Development Company Of Hebrew University Of Jerusalem Phospholipase a2 inhibiting compositions and their use
US5470578A (en) * 1992-07-30 1995-11-28 Seikagaku Kogyo Kabushiki Kaisha Antirheumatic composition
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232013A (en) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk Nasal drop
ES2044781B1 (en) * 1992-04-14 1994-10-01 Menarini Lab PROCEDURE FOR THE PREPARATION OF NEW AMIDES WITH PHOSPHOLIPASE A2 INHIBITING ACTION
WO1996011670A1 (en) * 1994-10-14 1996-04-25 The Liposome Company, Inc. Ether lipid liposomes and their therapeutic use
JPH11147901A (en) * 1997-11-19 1999-06-02 Maruho Co Ltd Kallikrein-kinin system inhibitor
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
EP2845596A3 (en) * 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064817A (en) * 1987-10-23 1991-11-12 Yissum Research Development Company Of Hebrew University Of Jerusalem Phospholipase a2 inhibiting compositions and their use
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5470578A (en) * 1992-07-30 1995-11-28 Seikagaku Kogyo Kabushiki Kaisha Antirheumatic composition
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions

Also Published As

Publication number Publication date
EP1819345A4 (en) 2012-04-18
IL212214A0 (en) 2011-06-30
WO2006054304A2 (en) 2006-05-26
EA200701077A1 (en) 2008-04-28
MX2007005975A (en) 2007-10-08
JP2012001559A (en) 2012-01-05
CN101175499A (en) 2008-05-07
BRPI0516810A (en) 2008-09-23
CA2587883A1 (en) 2006-05-26
JP2008520650A (en) 2008-06-19
IL183227A0 (en) 2007-08-19
AU2005305456B2 (en) 2011-05-19
EP1819345A2 (en) 2007-08-22
EA012138B1 (en) 2009-08-28
IL212215A0 (en) 2011-06-30
AU2005305456A1 (en) 2006-05-26
CN101175499B (en) 2010-12-22

Similar Documents

Publication Publication Date Title
WO2006054304A3 (en) Use of lipid conjugates in the treatment of disease
US20200155545A1 (en) Metap2 inhibitors and methods of treating obesity
EP2305639A3 (en) Organic compounds
IL176416A (en) Prostaglandin nitrooxy derivatives, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for treating glaucoma or ocular hypertension
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
WO2005112914A3 (en) Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
WO2007117605A3 (en) Novel spill-resistant formulations comprising hydrocolloidal polymers
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2007073560A3 (en) Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
IL168704A (en) Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
WO2006029487A3 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
MX2010012019A (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.
WO2007144902A8 (en) Chewable bilayer tablet formulation
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2007041681A3 (en) Methods for treating respiratory disorders
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 183227

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007542507

Country of ref document: JP

Ref document number: 2587883

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005975

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2005305456

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005305456

Country of ref document: AU

Date of ref document: 20051117

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005305456

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2005808267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005808267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200701077

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200580046771.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005808267

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0516810

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 212214

Country of ref document: IL

Ref document number: 212215

Country of ref document: IL